Heated chemo during surgery: a new hope for ovarian cancer?
NCT ID NCT05415709
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether giving heated chemotherapy directly into the abdomen during surgery is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants will receive standard chemotherapy before surgery, and then either heated chemo during surgery or extra chemo the day before. The study aims to see which approach has fewer side effects and is more practical.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cisplatin (heated chemotherapy given into the abdomen during surgery)
- What this could lead to
- If this approach is safe and feasible, it could lead to a larger trial testing whether heated chemotherapy during surgery helps people with advanced ovarian cancer live longer.
- What could go wrong
- This is a very early (Phase 1) trial with only 45 people. It is designed to check safety, not effectiveness. Heated chemotherapy can cause serious side effects like infection, organ damage, or blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill target Hard-to-Treat ovarian cancers?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug combo aims to improve ovarian cancer maintenance with fewer dropouts
- Major trial tests if abdominal chemo beats IV for tough cancers